TBCA

TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases[1][2].

Product Specifications

CAS Number

[934358-00-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Casein Kinase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tbca.html

Concentration

10mM

Purity

99.45

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(/C=C/C1=C(C(Br)=C(Br)C(Br)=C1)Br)=O

Molecular Formula

C9H4Br4O2

Molecular Weight

463.74

Precautions

H315, H319, H335

References & Citations

[1]Pagano MA, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8 (1) :129-139.|[2]Ryu SY, Kim S. Evaluation of CK2 inhibitor (E) -3- (2,3,4,5-tetrabromophenyl) acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013;720 (1-3) :391-400.